

Safe Genetic Modification of Cardiac Stem Cells Using a Site-Specific Integration Technique

Feng Lan, Junwei Liu, Kazim H. Narsinh, Shijun Hu, Leng Han, Andrew S. Lee, Marisa Karow, Patricia K. Nguyen, Divya Nag, Michele P. Calos, Robert C. Robbins and Joseph C. Wu

Circulation. 2012;126:S20-S28

doi: 10.1161/CIRCULATIONAHA.111.084913

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2012 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circ.ahajournals.org/content/126/11_suppl_1/S20

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation* is online at:
<http://circ.ahajournals.org/subscriptions/>

Cell Transplantation and Tissue Regeneration

Safe Genetic Modification of Cardiac Stem Cells Using a Site-Specific Integration Technique

Feng Lan, PhD*; Junwei Liu, MD*; Kazim H. Narsinh, MD*; Shijun Hu, PhD; Leng Han, PhD; Andrew S. Lee, BS; Marisa Karow, PhD; Patricia K. Nguyen, MD; Divya Nag; Michele P. Calos, PhD; Robert C. Robbins, MD; Joseph C. Wu, MD, PhD

Background—Human cardiac progenitor cells (hCPCs) are a promising cell source for regenerative repair after myocardial infarction. Exploitation of their full therapeutic potential may require stable genetic modification of the cells *ex vivo*. Safe genetic engineering of stem cells, using facile methods for site-specific integration of transgenes into known genomic contexts, would significantly enhance the overall safety and efficacy of cellular therapy in a variety of clinical contexts.

Methods and Results—We used the phiC31 site-specific recombinase to achieve targeted integration of a triple fusion reporter gene into a known chromosomal context in hCPCs and human endothelial cells. Stable expression of the reporter gene from its unique chromosomal integration site resulted in no discernible genomic instability or adverse changes in cell phenotype. Namely, phiC31-modified hCPCs were unchanged in their differentiation propensity, cellular proliferative rate, and global gene expression profile when compared with unaltered control hCPCs. Expression of the triple fusion reporter gene enabled multimodal assessment of cell fate *in vitro* and *in vivo* using fluorescence microscopy, bioluminescence imaging, and positron emission tomography. Intramyocardial transplantation of genetically modified hCPCs resulted in significant improvement in myocardial function 2 weeks after cell delivery, as assessed by echocardiography ($P=0.002$) and MRI ($P=0.001$). We also demonstrated the feasibility and therapeutic efficacy of genetically modifying differentiated human endothelial cells, which enhanced hind limb perfusion ($P<0.05$ at day 7 and 14 after transplantation) on laser Doppler imaging.

Conclusions—The phiC31 integrase genomic modification system is a safe, efficient tool to enable site-specific integration of reporter transgenes in progenitor and differentiated cell types. (*Circulation*. 2012;126[suppl 1]:S20–S28.)

Key Words: cell therapy ■ stem cells ■ imaging ■ cardiovascular disease

Cardiovascular disease remains one of the leading causes of morbidity and mortality in the United States and globally. After a myocardial infarction, the limited proliferative ability of the surviving myocardial cells renders the heart susceptible to morbid sequelae such as unfavorable remodeling and ischemic cardiomyopathy. Recently, stem cell therapy has emerged as a promising adjunct to existing pharmacological and device treatment options.^{1,2} In particular, human cardiac progenitor cells (hCPCs) are attractive candidates for clinical translation of cell therapy.³ hCPCs can be autologously derived, obviating the need for immune suppression after transplantation, and are preprogrammed for differentiation into the three principal cardiovascular lin-

eages: cardiomyocytes, vascular endothelial cells, and smooth muscle cells. Preclinical studies in small and large animals have thus far affirmed the beneficial effect of CPC transplantation on recipient myocardial function.^{4–6} More recently, phase I clinical trials have demonstrated improved left ventricular (LV) ejection fraction⁷ or reduced scar mass and improved regional systolic wall thickening⁸ at 4–6 months after infusion of hCPCs for treatment of acute myocardial infarction.

Despite these promising initial results, little is known regarding important questions such as the optimal cell dose or delivery method, the rate of *in vivo* cellular survival, proliferation, engraftment and differentiation, or the mechanism(s)

From the Department of Medicine, Division of Cardiology (F.L., J.L., K.H.N., S.H., L.H., A.S.L., P.K.N., D.N., J.C.W.), the Department of Radiology (F.L., J.L., K.H.N., S.H., L.H., A.S.L., P.K.N., D.N., J.C.W.), the Department of Genetics (M.K., M.P.C.), the Department of Cardiothoracic Surgery (R.C.R.), Stanford Cardiovascular Institute (R.C.R., J.C.W.), and Institute for Stem Cell Biology and Regenerative Medicine (J.C.W.), Stanford School of Medicine, Stanford, CA.

*Drs Lan, Liu and Narsinh contributed equally to this study.

Finalist for the 2011 Vivien Thomas Award.

Presented at the 2011 American Heart Association meeting in Orlando, FL, November 13–17, 2011.

The online-only Data Supplement is available at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.084913/-DC1>.

Correspondence to Joseph C. Wu, MD, PhD, Lorrey Lokey Stem Cell Research Bldg, 265 Campus Dr, Room G1120B, Stanford, CA 94305–5111. E-mail joewu@stanford.edu

© 2012 American Heart Association, Inc.

Circulation is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.111.084913

of potential therapeutic benefit in clinical hCPC trials. Transplantation of stem cell therapy has also been limited by poor engraftment and survival^{9,10} as well as unpredictable differentiation in vivo.^{11,12} In recent years, stem cell imaging has emerged as a valuable tool to quantitatively address some of these variables, and its implementation in clinical trials could add novel insight into the determinants of successful stem cell therapy.¹³ Genetic engineering of stem cells is currently being explored as a means to image transplanted cells as well as overcome the aforementioned challenges. Stable ex vivo gene transfer into stem cells before their transplantation can be used to enhance stem cell homing,¹⁴ survival,¹⁵ imaging,¹⁶ and targeted ablation.^{16,17} However, genetic engineering is limited by many of the challenges facing the gene therapy field at large. In particular, several current gene therapy approaches rely on retrovirus, lentivirus, or transposon elements, which catalyze random transgene integration into many potential sites. Randomly integrating vectors are not safe for clinical use because insertional mutagenesis can cause oncogenic activation and malignant transformation of cells.¹⁸ Safe techniques for site-specific integration of transgenes into the human genome are therefore needed to overcome these shortcomings.

The phiC31 integrase is a site-specific recombinase that can be used to integrate transgenes into specific loci of the human genome. Specifically, the phiC31 integrase catalyzes recombination between *attB* and *attP* attachment sites, which are DNA recognition sequences of substantial size (≈ 17 bp). This enzyme can therefore be used to integrate a transgene-containing plasmid carrying an *attB* site into pseudo-*attP* sites in the human genome. These specific loci of the human genome are known to produce robust, long-term transgene expression without risking proto-oncogene activation.¹⁹ In the present study, we used this site-specific integration system to safely derive hCPC clones capable of long-term in vivo monitoring by using positron emission tomography (PET) or bioluminescence imaging (BLI). The resulting hCPCs are safe for use in humans because of their precisely known genetic makeup. Importantly, in addition to reporter gene imaging, this technique can be used to introduce a variety of genetic constructs safely and efficiently for enhanced cardiac stem cell therapy.

Methods

Isolation, Culture, and Characterization of Human Cardiac Progenitor Cells

Human CPCs were isolated based on a previously described protocol using magnetic separation in conjunction with a Sca-1 antibody.^{20–22} The study protocol was approved by the Stanford Institutional Review Board. In brief, human fetal hearts (StemExpress, Diamond Springs, CA) were perfused using a Langendorff apparatus, using Tyrode solution containing collagenase and protease. hCPCs were isolated by magnetic cell sorting (MACS, Miltenyl Biotec, Sunnyvale, CA), using Sca-1-coupled magnetic beads, according to the manufacturer's protocol. Sca-1⁺ cells were eluted from the column by washing with PBS supplemented with 2% FBS and cultured on 0.1% gelatin-coated dishes in M199 (Gibco)/EGM-2 (3:1) supplemented with 10% FCS (Gibco), 10 ng/mL basic fibroblast growth factor (bFGF), 5 ng/mL epithelial growth factor (EGF), 5 ng/mL insulin-like growth factor (IGF-1), and 5 ng/mL hepatocyte growth factor (HGF). For isolation of human endothelial cells (hECs), please

see the Online Data Supplement Methods for details. All hCPCs (unmodified and genetically modified) used for in vitro experiments and intramyocardial injection were at passage 10 to 16.

Flow Cytometry Analysis

Please see Online Data Supplement Methods for details.

Plasmid Constructs and Generation of Site-Specific Integrated Cell Lines

The donor construct pDB-FRT was generated by replacing the cassette coding GFP in a donor vector pDB2²³ containing an *attB* site with a triple fusion gene.²⁴ The plasmid pCSI expressing phiC31 integrase has been described.²⁵ To construct the donor plasmid pDB-FRT, a triple fusion gene coding firefly luciferase (Fluc), monomeric red fluorescent protein (mRfp), and herpes simplex virus truncated thymidine kinase (HSVtk) was cloned downstream of the CMV promoter. The hCPCs and hECs were grown and transfected with Fugene6, according to the manufacturer's instructions, using 3 μ L of reagent per 1 μ g of DNA. Transfections yielding integrase-derived clones used 10 ng of pDB-FRT and 5 μ g of pCSI. After 24 hours, cells were split 1:30 to three 10-cm plates. At 48 hours after transfection, cells were selected in medium containing 350 μ g/mL of G418 (Invitrogen). Selection was continued for 10 to 14 days, at which time colonies became visible. Individual colonies were picked with a pipette tip and transferred to individual wells of a 24-well plate. Surviving colonies were expanded for PCR analysis. To screen for site-specific integrations, a nest PCR method using primers targeting 11 most frequent integration sites was used as described previously.¹⁹ Briefly, a set of 11 primers were used for the first-round PCR to amplify the integration genes from the genomic DNA extracted from individual clones. The clones with site-specific integration demonstrated the expected size second-round PCR product and were selected for further characterization and functional studies.

Effect of Reporter Gene Expression on hCPC Viability, Proliferation, and Differentiation

Please see Online Data Supplement Methods for details.

In Vitro [¹⁸F]-FHBG Accumulation Assay

Please see Online Data Supplement Methods for details.

Microarray Hybridization and Data Analysis

Please see Online Data Supplement Methods for details.

Surgical Model of Mouse Myocardial Infarction and hCPC Delivery

In adult female SCID Beige mice (Charles River Laboratories, Wilmington, MA), myocardial infarction (MI) was induced by ligation of the left coronary artery under 1.5% to 2% inhaled isoflurane anesthesia and confirmed by myocardial blanching and ECG changes. Animals were randomized into experimental groups receiving phiC31-hCPCs (n=30) or unmodified hCPCs (n=15) and a control group receiving PBS (n=15). All experimental animals were injected with 1×10^6 cells, using a 31-gauge Hamilton syringe immediately after MI. In all groups, the volume of injection was 20 μ L at 3 sites near the peri-infarct border zone. All surgical procedures and injections were performed by a blinded, experienced microsurgeon (Y.G.).

In Vivo Optical BLI of Cell Survival in Transplanted Animals

Please see Online Data Supplement Methods for details.

[¹⁸F]-FHBG PET Imaging of Cell Survival in Transplanted Animals

Please see Online Data Supplement Methods for details.




Figure 1. Site-specific integration of triple fusion reporter gene into human cardiac progenitor cells (hCPCs). **A**, An integration vector plasmid encoding the phiC31 integrase (purple) and a donor vector plasmid encoding the triple fusion (TF) reporter gene (green) were initially cotransfected into hCPCs. Next, positive integrants were identified using neomycin selection. Individual colonies grown from single cells were then picked and expanded for further characterization. **B**, Genomic DNA of the neomycin-resistant hCPC population was isolated and subjected to PCR analysis with a known set of primers to identify integration at specific loci located on chromosomes 19, 21, and X. **C**, Twenty individually expanded hCPC colonies grown from single cells were screened for integration at loci on chromosomes 19 and 21. Clone No. 7 revealed a single integration of the triple fusion reporter gene at a site on chromosome 21, whereas clone No. 16 revealed a single integration at a site on chromosome 19. **D**, Site-specific integration of the triple fusion reporter gene occurs uniquely at a “safe harbor” site located on chromosome 19.

Analysis of LV Function With Echocardiography and MRI

Echocardiography was performed before (day -7) and after (day 2, week 1, week 2, week 3, and week 4) the LAD ligation. The Siemens-Acuson Sequoia C512 system equipped with a multifrequency (8–14 MHz) 15L8 transducer was used by an experienced operator (P.K.N.) blinded to the group designation. Analysis of M-mode images was performed using Siemens built-in software. LV volume at end of diastolic diameter (EDD) and end-systolic diameter (ESD), and volume of blood at end of diastole (BED) were measured and used to calculate LV ejection fraction by the formula: $LVFS = [EDD - ESD] / BED$. MRI was performed on a Sigma 3.0-T Excite HD scanner (GE Healthcare Systems, Milwaukee, WI) with a Mayo Clinic T/R MRI coil (Mayo Clinic Medical Devices, Rochester, MI) in a subset of animals ($n = 5$ /group). Mice were anesthetized with 2% isoflurane with oxygen (1 L/min) and placed in the prone position for imaging. A small-animal ECG and respiratory gating system (Small Animal Instruments, Stony Brook, NY) was used to acquire images as previously described.²⁶

Delivery of hECs in a Hind Limb Ischemia Model

Please see Online Data Supplement Methods for details.

Laser Doppler Perfusion Imaging

Blood flow to the ischemic or normal (nonischemic) hind limb was assessed using a PeriScan PIM3 laser Doppler system (Perimed AB, Stockholm, Sweden) as described previously.²⁷ Each animal was prewarmed to a core temperature of 37°C, and hind limb blood flow was measured before and after surgery on day 0 and again on days 3, 7, and 14. Regions of interest of the ischemic or nonischemic hind limb were drawn in a standard fashion. The level of perfusion in the ischemic and normal hind limbs was quantified using the mean pixel value within the region of interest, and the relative changes in hind limb blood flow were expressed as the ratio of the left (ischemic) over right (normal) mean pixel value.

Histological Examination

Please see Online Data Supplement Methods for details.

Statistical Analysis

Statistics were calculated using SPSS 12.0 (SPSS Inc, Chicago, IL). Descriptive statistics included mean and standard deviation. One-way ANOVA and 2-way repeated-measures ANOVA with post hoc testing were used. Differences were considered significant at probability values of < 0.05 .




Figure 2. In vitro comparison of triple fusion reporter gene-expressing human cardiac progenitor cells (hCPCs) derived using site-specific phiC31 integrase recombination versus random lentiviral infection. **A**, The phiC31-hCPCs show unaltered Mef2C and Nkx2.5 cardiac progenitor gene expression and can differentiate into cardiomyocytes, smooth muscle (SM), and endothelial cells similar to unmodified control hCPCs. **B**, The phiC31-hCPCs and the unmodified control hCPCs have similar global gene expression patterns as assessed by transcriptome microarrays and are different from the human embryonic stem cell line (hESC-H7). **C**, Representative bioluminescence imaging of known numbers of hCPCs derived using site-specific phiC31 recombination or random lentiviral integration. **D**, Representative microPET images of known numbers of hCPCs during the [18 F]-FHBG accumulation assay. Relative PET signal was normalized to the maximum background level at 120 minutes.

Results

phiC31 Integrase Mediates Site-Specific Integration of the Triple Fusion Reporter Gene

A donor vector containing the triple fusion reporter gene was designed as shown in Figure 1A. The triple fusion reporter gene encodes firefly luciferase (Fluc), monomeric red fluorescent protein (mRFP), and HSVtk to enable multimodal imaging using bioluminescence, fluorescence, and PET, respectively. This vector was cotransfected with the integration vector containing the phiC31 integrase into 293 cells to validate the site-specific integration system. The transfected cells were cultured in neomycin for 3 weeks to select stably-integrated cell clones. Genomic DNA was isolated from these clones, and primers for 3 typical integration sites were used to screen for site-specific integration of the triple fusion reporter transgene (Online Data Supplement Figure I). As expected, only the cells transfected with phiC31 integrase

showed an appropriately sized PCR product, indicating unique transgene insertion at the intended genomic site.

Isolation and Derivation of Genetically Modified hCPC

We first isolated Sca-1⁺ hCPCs from human fetal hearts and clonally expanded them using a previously described protocol.²¹ The purity of the isolated progenitor cells was confirmed by cell surface marker expression (Online Data Supplement Figure II). Then, one 60-mm cell culture dish containing approximately 1×10^6 hCPCs was cotransfected with the donor and integration plasmids as shown in Figure 1A. After 3 weeks of growth in selection media containing neomycin, an average of 57 colonies was obtained (see Online Data Supplement Methods). Control transfections of the donor plasmid only (without the integration plasmid) yielded only 1 to 2 neomycin-resistant colonies, suggesting that transient expression of the phiC31 integrase substantially improved the rate of site-specific recombination. We

then screened the genomic DNA of hCPCs for integration using a set of 44 pairs of primers.¹⁹ The genomic DNA of pooled neomycin-resistant hCPCs reliably demonstrated integration in 3 well-characterized integration sites on chromosomes 19, 21, and X (19q13, 21q21, and Xq22; Figure 1B; also see Online Data Supplement Methods). We screened 20 arbitrarily selected clones with 8p22, 19q13, 21q21, and Xq22 primers. From these 20 clones, we obtained 2 clones with a single integration: clone 16 contained a single integration at the 19q13 site and clone 7 contained a single integration at the 21q21 site (Figure 1C). Of note, only single integration sites were found in the clones obtained using phiC31 integration, whereas clones derived in parallel using lentiviral vectors displayed multiple integration sites, as evaluated by Southern blotting (Online Data Supplement Figure III). We then chose the hCPC clone with known integration at the 19q13 site (Figure 1D) for subsequent functional experiments (designated phiC31-hCPCs).

Site-Specific Integration of the Triple Fusion Reporter Gene Does Not Alter hCPC Phenotype and Enables Robust Transgene Expression

Expression of the reporter gene from the “safe harbor” locus on chromosome 19 did not affect the cellular phenotype of hCPCs. Namely, integration of the reporter gene using phiC31 caused no discernible adverse effects on cellular proliferation (Online Data Supplement Figure IV), karyotype (Online Data Supplement Figure V), or gene expression profile (Online Data Supplement Figure VI). Of note, hCPC clones derived using lentivirus did display a relative deficit in cellular proliferation capacity at 72 and 96 hours compared with untransduced hCPCs (Online Data Supplement Figure IV). Most importantly, derivation of hCPC clones using phiC31 did not appreciably affect the differentiation propensity of hCPCs. phiC31-hCPCs retained expression of the Mef2C and Nkx2.5 cardiac transcription factors, as well as their ability to differentiate into cardiomyocyte, smooth muscle, and endothelial cell lineages, as evidenced by expression of the α -actinin, smooth muscle actin (SMA), or CD31 markers, respectively (Figure 2A and Online Data Supplement Figure VII). The gene expression profile of phiC31-hCPCs, as assessed by transcriptome microarray, was no different than that of untransduced hCPCs (Figure 2B). Finally, expression of the triple fusion reporter gene (Fluc-mRFP-HSVtk) from the 19q13 site was stable and robust. Fluc activity correlated linearly with cell number ($R^2=0.99$), as shown in Figure 2C and Online Data Supplement Figure VIII. Bioluminescent signal intensity did not decrease appreciably over multiple passages (Online Data Supplement Figure IX), indicating that “gene silencing” played a negligible role in interpretation of the results. Uptake of 9-[4-¹⁸F]fluoro-3-(hydroxymethyl)butyl]guanine ([¹⁸F]-FHBG) radiotracer increased linearly over time in both phiC31-modified hCPCs and lentivirally modified hCPCs, signifying robust HSVtk activity (Figure 2D and Online Data Supplement Figure VIII). As expected, HSVtk activity was diminished in phiC31-modified hCPCs containing a single integration copy of the reporter gene, compared with lentivirally modified hCPCs that contained multiple randomly integrated copies of the reporter gene (Online Data Supplement Figure III).

Intramyocardial Transplantation of hCPCs Improves LV Contractility

We next tested the efficacy of hCPC transplantation in ameliorating the effects of MI in mice. Adult NOD SCID mice were subjected to left anterior descending (LAD) artery ligation followed by injection with 1×10^6 phiC31-hCPCs ($n=30$), 1×10^6 unmodified hCPCs ($n=15$), or PBS control ($n=15$). Myocardial LV function after hCPC transplantation was assessed by echocardiography (Figure 3A) and cardiac MRI (Online Data Supplement Figure X, A) over the 8-week study period. At week 2 after transplant, phiC31-hCPC-treated hearts demonstrated a statistically significant improvement in fractional shortening ($24.9 \pm 1.3\%$ versus $19.8 \pm 1.0\%$; $P=0.0017$; Figure 3B) and ejection fraction ($54.3 \pm 1.8\%$ versus $45.6 \pm 1.5\%$; $P=0.0008$; Online Data Supplement Figure X, B) compared with PBS controls. However, no statistically significant differences in contractility were observed between the hCPC-treated and untreated PBS controls at week 8 after transplant. As expected, the phiC31-hCPC-treated group did not display statistically significant differences from the unmodified hCPC-treated group at any of the tested time points.

Molecular Imaging of hCPC Survival in Ischemic Myocardium

We then evaluated the temporal kinetics of hCPC engraftment using BLI and PET. We carried out serial acquisitions concurrently over the 8-week study period and observed loss of both BLI and PET signal intensities over time, reflecting death of the transplanted cells (Figure 4A). When normalized to BLI signal intensity at day 1, the percentage of cells that survived was $22.7 \pm 11.5\%$ at day 7, $15.7 \pm 7.7\%$ at day 14, $10.6 \pm 5.1\%$ at day 28, and $0.8 \pm 0.4\%$ at day 56 (Figure 4B). These results were confirmed using PET imaging (Figure 4C and 4D) and are in agreement with the results of other groups showing death of the majority of transplanted stem cells within 4 to 6 weeks after intramyocardial delivery.^{9,28–30} To confirm the results of our PET and BLI data, we also measured cell engraftment using real-time quantitative polymerase chain reaction (RT-qPCR). To this end, we used human-specific primers against Alu sequences to quantify the number of human genomes present within murine hearts at 14 and 28 days after transplantation. Our results using RT-qPCR were concordant with data obtained using PET and BLI. Namely, at days 14 and 28 after transplantation, $12.12 \pm 3.33\%$ and $6.36 \pm 2.35\%$ of unmodified hCPCs had successfully engrafted into murine myocardium. Similarly, at days 14 and 28 after transplantation, $11.37 \pm 3.55\%$ and $6.65 \pm 2.46\%$ of phiC31-hCPCs had successfully engrafted (Online Data Supplement Figure XI).

Isolation and Site-Specific Genetic Modification of Differentiated hECs

Human CPCs represent a multipotent cell type with significant proliferative potential, which may account for the relative ease with which site-specific hCPC integrants can be obtained. We therefore wished to demonstrate site-specific integration in another cell type; in particular, a more differentiated cell source with therapeutic potential such as hECs.




Figure 3. Improvement in myocardial contractility after human cardiac progenitor cell (hCPC) transplant as assessed by echocardiography and MRI. **A**, Representative M-mode echocardiogram demonstrates functional improvement at week 2 in the hCPC group. **B**, The fractional shortening of hCPC groups shows significant improvement compared with PBS control group at week 2 ($P < 0.001$). There was no significant difference between the phiC31-hCPC and unmodified hCPC groups. **C**, Representative sections of the peri-infarct zone in the area of intramyocardial hCPC or PBS injection demonstrates the presence of phiC31-hCPCs. phiC31-hCPCs stained positive for the RFP antibody in the recipient myocardium at day 14 after injection. **D**, Representative hematoxylin and eosin staining of the heart sections show myocardial wall thickness of gross hearts at week 2 and week 6 after injection. **E**, Myocardial wall thickness of the hCPC groups are significantly increased compared with PBS control group at week 2 after transplantation. There was no significant difference between the phiC31-hCPC and unmodified hCPC groups. All hCPCs (unmodified and phiC31-modified) were transplanted intramyocardially at passage 10 to 16.

We generated hECs containing site-specific integration of the triple fusion reporter gene by cotransfection of donor and integration vectors (Figure 1A). The transfected cells were clonally expanded and screened for integration at known pseudo-*attP* sites.¹⁹ One of 20 clones was shown to have a single integration at the 8p22 site and was expanded for further characterization, and functional experiments phiC31-hECs were identical to untransduced hECs in their phenotype, as assessed by their expression of the endothelial cell marker CD31 (>90%), LDL uptake, and ability to form tubules in vitro (Online Data Supplement Figure XII).

Transplantation of hECs Improves Ischemic Limb Perfusion

To assess cellular engraftment over time, we used BLI to evaluate the temporal kinetics of hEC survival (Figure 5A). Normalized to day 1, the BLI signals were $37.6 \pm 5.5\%$ at day 4, $17.7 \pm 3.5\%$ at day 7, and $11.3 \pm 2.1\%$ at day 14 (Figure 5B). These results suggest acute death of hECs during the first week but relatively stable engraftment thereafter. We subsequently carried out laser Doppler blood perfusion (LDBP) monitoring to examine whether hEC delivery im-

proved ischemic hind limb perfusion (Figure 5C). The hind limb perfusion ratio (ischemic/control hind limb) was significantly improved in the hind limbs transplanted with hECs compared with PBS at day 7 (0.41 ± 0.05 versus 0.32 ± 0.04 , $P < 0.005$) and day 14 (0.54 ± 0.07 versus 0.41 ± 0.04 ; $P < 0.005$) after transplantation (Figure 5D). The hind limb perfusion ratios of phiC31-hECs and the unmodified hECs were similar. These data show that phiC31-hECs, despite their genetic modification, can be safely transplanted in vivo and retain their therapeutic capability to restore perfusion.

Discussion

In recent years, stem cell therapy has emerged as a promising approach to promote tissue repair after myocardial infarction. Despite encouraging initial results, clinical translation of cellular therapy has been impeded by several challenges, including poor engraftment,³¹ malignant transformation,³² or acute death of the transplanted cells.³³ Innovative approaches to overcome these challenges have relied on genetic modification of the delivered stem cells to enable expression of transgenes. Stable expression of such transgenes can enable a variety of valuable enhancements to cellular therapy, includ-




Figure 4. Temporal kinetics of human cardiac progenitor cells (hCPC) survival in infarcted hearts. **A** and **C**, Longitudinal bioluminescence imaging (BLI) and PET imaging of a representative adult female SCID mouse injected with 1×10^6 hCPCs stably expressing the triple fusion reporter gene. **B** and **D**, Progressive decrease in PET and BLI signal intensity over the 28-day time course. **B**, Normalized to day 1, BLI signals were $22.7 \pm 11.5\%$ on day 7, $15.7 \pm 7.7\%$ on day 14, and $10.6 \pm 5.1\%$ on day 28. **D**, Normalized to day 1, PET signals were $44.7 \pm 3.2\%$ on day 7, $22.4 \pm 1.6\%$ on day 14, $15.3 \pm 1.1\%$ on day 21, and $13.2 \pm 0.6\%$ on day 28.

ing enhanced vasculogenesis,³⁴ improved cell survival,^{15,35} cellular tracking using clinical imaging modalities,³⁶ and the availability of a “safety switch” to induce apoptosis in the event of cellular misbehavior.¹⁷ However, commonly used gene therapy vectors such as lentivirus and retrovirus can produce random integrations that are subject to the unpredictable effects of insertional mutagenesis. Hence, site-specific integration techniques are needed to safely translate gene therapy into the clinical setting.

In recent years, stem and progenitor cells have emerged as exciting new tools for ameliorating LV dysfunction after MI. hCPCs hold considerable potential in this regard, as they are a clonogenic, self-renewing population that is preprogrammed for differentiation into cells of all 3 cardiac lineages in vitro: myocytes, smooth muscle cells, and endothelial cells. Several parameters for hCPC identification are currently found in the literature, including isolation of c-kit⁺ cells,³ cardiosphere-derived cells,³⁷ Sca-1⁺ cells,²¹ and Isl1⁺ cells.³⁸ These various hCPC formulations have all demonstrated a degree of efficacy in animal studies, although evaluation of the degree of overlap between these various populations and their comparative efficacy is still needed. We used Sca-1⁺ hCPCs in this study, as we and others have found that hCPCs isolated using the Sca-1 antibody consistently provide high yields of homogeneous cells with identical morphology, differentiation, and surface marker expression.^{21,39,40} However, the human equivalent for murine Sca-1 has not yet been identified. Presumably, the Sca-1 antibody cross-reacts with a

human protein to yield a homogeneous population, but further work is needed to elucidate the identity of this epitope.

In the present study, we used the phiC31 integrase to achieve site-specific integration of a triple fusion reporter gene into a known chromosomal context in hCPCs and hECs. This proof-of-principle study demonstrates the utility of the phiC31 integration technique in producing both progenitor cells (hCPCs) and differentiated cells (hECs) that have been genetically modified to stably express a transgene of interest. Moreover, the techniques described herein are easily applied in any context with just basic molecular biology expertise and plasmid manipulation tools.⁴¹ Genomic modification of hCPCs did not appreciably alter the progenitor cell phenotype, as assessed by global transcriptome microarray analysis and immunohistochemical analysis of differentiating progenitor cells. Indeed, phiC31-modified hCPCs retained their ability to improve myocardial contractility by a statistically significant margin compared with controls when assessed 2 weeks after intramyocardial injection. Likewise, phiC31-modified hECs maintained their ability to improve ischemic hind limb perfusion after genomic modification.

We have found the phiC31 integrase technique a facile and efficient approach for generating site-specific integrants in progenitor and differentiated cells. Alternate site-specific integration techniques are significantly less efficient than phiC31-integrase mediated recombination because they often rely on successful activation of the mammalian cell homologous recombination machinery. One such technique in-




Figure 5. Improvement in hind limb perfusion after transplantation of human endothelial cells (hECs). **A**, Localization and survival of phiC31-human endothelial cells in the ischemic hind limb after intramuscular delivery as assessed by bioluminescence imaging (BLI). **B**, Quantification of BLI signal in the hind limb after cell delivery. **C**, Representative laser Doppler perfusion images of an adult female SCID Beige mouse injected with 1×10^6 unmodified hECs or 1×10^6 phiC31-hECs at 1, 3, 7, and 14 days after cell delivery showing improved blood flow for the treatment group relative to PBS controls. **D**, The mean hind limb perfusion ratio (ischemic/control hind limb) was significantly improved in hEC-treated mice compared with the PBS-treated mice ($*P < 0.05$, transplant groups versus control groups at day 14 after transplant). There was no significant difference between the phiC31-hEC and unmodified hEC groups ($n = 5$ per group).

volves the introduction of a double-strand break at the desired genomic location by a tandem pair of zinc-finger nucleases (ZFNs).⁴² Although ZFNs allow targeting of a wider variety of genomic loci, their design and validation require extensive time and expertise. In addition to verifying proper targeting, cell exposure to ZFNs must be minimized in order to prevent any off-target cleavage events. The phiC31 integrase system is easily implemented using common plasmid manipulation and molecular biology techniques.

In summary, our report establishes for the first time the feasibility of site-specific genetic integration in human cardiac progenitor cells and human endothelial cells using nonviral vectors. This type of genetic engineering of human stem cells enables a multitude of improvements to overcome many of cellular therapy's current limitations. The ease, efficiency, and safety of the phiC31 integrase system make it an appealing approach to such attempts at stable genetic modification of therapeutic cell populations.

Acknowledgments

We would like to acknowledge Fangjun Jia, Yongquan Gong, and Li Wang for helpful discussions as well as assistance with experimental protocols.

Sources of Funding

This work was supported in part by grants from Burroughs Wellcome Foundation, NIH HL093172, NIH EB009689, and NIH HL 095571 (J.C.W.), and NIH HL099776 (R.C.R.).

Disclosures

M.P.C. is an inventor on Stanford-owned patents covering phiC31 integrase.

References

- Rasmussen TL, Raveendran G, Zhang J, Garry DJ. Getting to the heart of myocardial stem cells and cell therapy. *Circulation*. 2011;123:1771–1779.
- Jameel MN, Zhang J. Stem cell therapy for ischemic heart disease. *Antioxid Redox Signal*. 2010;13:1879–1897.
- Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins RW, LeCapitaine N, Cascapera S, Beltrami AP, D'Alessandro DA, Zias E, Quaini F, Urbanek K, Michler RE, Bolli R, Kajstura J, Leri A, Anversa P. Human cardiac stem cells. *Proc Natl Acad Sci U S A*. 2007;104:14068–14073.
- Tang X-L, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, Dai S, Li C, Chen N, Peng Y, Dawn B, Hunt G, Leri A, Kajstura J, Tiwari S, Shirk G, Anversa P, Bolli R. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. *Circulation*. 2010;121:293–305.
- Cheng K, Li T-S, Malliaras K, Davis DR, Zhang Y, Marban E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. *Circ Res*. 2010;106:1570–1581.
- Lee S-T, White AJ, Matsushita S, Malliaras K, Steenbergen C, Zhang Y, Li T-S, Terrovitis J, Yee K, Simsir S, Makkar R, Marban E. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. *J Am Coll Cardiol*. 2011;57:455–465.
- Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marban L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marban E. Intracoronary cardiosphere-

- derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomized phase I trial. *Lancet*. 2012; 379:895–904.
8. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac Stem Cells In Patients With Ischaemic Cardiomyopathy (SCIPIO): initial results of a randomised phase I trial. *Lancet*. 2011;378:1847–1857.
 9. Li Z, Lee A, Huang M, Chun H, Chung J, Chu P, Hoyt G, Yang P, Rosenberg J, Robbins RC, Wu JC. Imaging survival and function of transplanted cardiac resident stem cells. *J Am Coll Cardiol*. 2009;53:1229–1240.
 10. Cao F, Wagner RA, Wilson KD, Xie X, Fu J-D, Drukker M, Lee A, Li RA, Gambhir SS, Weissman IL, Robbins RC, Wu JC. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. *PLoS One*. 2008;3:e3474.
 11. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. *Nature*. 2004;428:668–673.
 12. Noiseux N, Gnechchi M, Lopez-Illasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, Pratt RE. Mesenchymal stem cells overexpressing AKT dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. *Mol Ther*. 2006;14:840–850.
 13. Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: guiding the clinical translation of cardiac stem cell therapy. *Circ Res*. 2011;109:962–979.
 14. Huang J, Zhang Z, Guo J, Ni A, Deb A, Zhang L, Mirosou M, Pratt RE, Dzau VJ. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. *Circ Res*. 2010;106:1753–1762.
 15. Fischer KM, Cottage CT, Wu W, Din S, Gude NA, Avitabile D, Quijada P, Collins BL, Fransioli J, Sussman MA. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing PIM-1 kinase. *Circulation*. 2009;120:2077–2087.
 16. Cao F, Lin S, Xie X, Ray P, Patel M, Zhang X, Drukker M, Dylla SJ, Connolly AJ, Chen X, Weissman IL, Gambhir SS, Wu JC. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. *Circulation*. 2006;113:1005–1014.
 17. Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. *N Engl J Med*. 2011;365:1673–1683.
 18. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulfraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science*. 2003; 302:415–419.
 19. Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT, Hoelters J, Calos MP. Integration specificity of phage phiC31 integrase in the human genome. *J Mol Biol*. 2006;357:28–48.
 20. Goumans MJ, de Boer TP, Smits AM, van Laake LW, van Vliet P, Metz CH, Korfage TH, Kats KP, Hochstenbach R, Pasterkamp G, Verhaar MC, van der Heyden MA, de Kleijn D, Mummery CL, van Veen TA, Sluijter JP, Doevendans PA. TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. *Stem Cell Res*. 2007;1:138–149.
 21. Smits AM, van Vliet P, Metz CH, Korfage T, Sluijter JP, Doevendans PA, Goumans MJ. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. *Nat Protoc*. 2009;4:232–243.
 22. van Vliet P, Roccio M, Smits AM, van Oorschot AA, Metz CH, van Veen TA, Sluijter JP, Doevendans PA, Goumans MJ. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. *Neth Heart J*. 2008;16:163–169.
 23. Keravala A, Portlock JL, Nash JA, Vitrant DG, Robbins PD, Calos MP. PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints. *J Gene Med*. 2006;8:1008–1017.
 24. Ray P, Tsien R, Gambhir SS. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. *Cancer Res*. 2007;67:3085–3093.
 25. Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP. Site-specific genomic integration produces therapeutic factor IX levels in mice. *Nat Biotechnol*. 2002;20:1124–1128.
 26. Huang M, Nguyen P, Jia F, Hu S, Gong Y, de Almeida PE, Wang L, Nag D, Kay MA, Giaccia AJ, Robbins RC, Wu JC. Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction. *Circulation*. 2011;124(11 Suppl):S46–S54.
 27. Niyama H, Kai H, Yamamoto T, Shimada T, Sasaki K, Murohara T, Egashira K, Imaizumi T. Roles of endogenous monocyte chemoattractant protein-1 in ischemia-induced neovascularization. *J Am Coll Cardiol*. 2004;44:661–666.
 28. Terrovitis J, Lautamaki R, Bonios M, Fox J, Engles JM, Yu J, Leppo MK, Pomper MG, Wahl RL, Seidel J, Tsui BM, Bengel FM, Abraham MR, Marban E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. *J Am Coll Cardiol*. 2009;54:1619–1626.
 29. van der Bogt KE, Sheikh AY, Schrepfer S, Hoyt G, Cao F, Ransohoff KJ, Swijnenburg RJ, Pearl J, Lee A, Fischbein M, Contag CH, Robbins RC, Wu JC. Comparison of different adult stem cell types for treatment of myocardial ischemia. *Circulation*. 2008;118:S121–S129.
 30. Johnston PV, Sasano T, Mills K, Evers R, Lee S-T, Smith RR, Lardo AC, Lai S, Steenbergen C, Gerstenblith G, Lange R, Marban E. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. *Circulation*. 2009;120:1075–1083.
 31. Schachinger V, Aicher A, Dobert N, Rover R, Diener J, Fichtlscherer S, Assmus B, Seeger FH, Menzel C, Brenner W, Dimmeler S, Zeiher AM. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. *Circulation*. 2008;118:1425–1432.
 32. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. *PLoS Med*. 2009;6:e1000029.
 33. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. *Eur Heart J*. 2006;27:1114–1122.
 34. Yang F, Cho S-W, Son SM, Bogatyrev SR, Singh D, Green JJ, Mei Y, Park S, Bhang SH, Kim B-S, Langer R, Anderson DG. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. *Proc Natl Acad Sci U S A*. 2010;107:3317–3322.
 35. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. *J Am Coll Cardiol*. 2005;46:1339–1350.
 36. Chen IY, Wu JC. Cardiovascular molecular imaging. *Circulation*. 2011; 123:425–443.
 37. Davis DR, Zhang Y, Smith RR, Cheng K, Terrovitis J, Malliaras K, Li T-S, White A, Makkar R, Marban E. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. *PLoS ONE*. 2009;4:e7195.
 38. Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, Shao Y, Roberts DJ, Huang PL, Domian IJ, Chien KR. Human Isl1 heart progenitors generate diverse multipotent cardiovascular cell lineages. *Nature*. 2009;460:113–117.
 39. van Oorschot AAM, Smits AM, Pardali E, Doevendans PA, Goumans M-J. Low oxygen tension positively influences cardiomyocyte progenitor cell function. *J Cell Mol Med*. 2011;15:2723–2734.
 40. Ryzhov S, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I. Role of a2b adenosine receptors in regulation of paracrine functions of stem cell antigen 1-positive cardiac stromal cells. *J Pharmacol Exp Ther*. 2012;341:764–774.
 41. Keravala A, Calos MP. Site-specific chromosomal integration mediated by phiC31 integrase. *Methods Mol Biol*. 2008;435:165–173.
 42. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet*. 2010;11:636–646.